Manufacturers report ertugliflozin meets primary endpoint in VERTIS CV trial for patients with type 2 diabetes and atherosclerotic cardiovascular disease

In the study, non-inferiority for major adverse CV events was confirmed vs placebo (11.9% for all arms, p<0.001 for non-inferiority). There was a 30% reduction in hospitalisation for heart failure for ertugliflozin vs placebo (2.5% vs 3.6%, HR 0.70, 95% CI 0.54-0.90).


Biospace Inc.